Results 111 to 120 of about 1,716,115 (264)

Histone deacetylase enzyme activity is not the universal anticancer target of HDAC inhibitors. [PDF]

Signal Transduct Target Ther
Rai C, Ruan H, Li X, Li W, Jeong HH, Song C, Liu P, Chang Y, Fang H, Kumar S U, Sun Y, You MJ, Guan D, Liu Z, Han L, Hou X, Sun Z.   +16 more
europepmc   +1 more source

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola, Yasmine Illi, Anna Bircher, Marijn Wilmink, Rachele F. Malagutti, Solenn Ottié, Cordelia Schuler, Pedro A. Ruiz, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Martin Hausmann   +11 more
wiley   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

ADA2 genotype and enzyme activity may predict vasculitic or hematologic DADA2 phenotype. [PDF]

J Hum Immun
Peters P, Schepp J, Albert MH, von Bernuth H, Blank N, Brunner J, Dückers G, Ehlers L, Farmand S, Föll D, Förster-Waldl E, Gburek-Augustat J, Ghosh S, Göschl L, Hömberg M, Hönig M, Kallinich T, Klemann C, Klingel L, Kontny U, Kuhn LM, Lamprecht P, Lehmberg K, Meyer-Bahlburg A, Müller I, Nathrath M, Niehues T, Oommen PT, Pachlopnik Schmid J, Prader S, Puzik A, Renella R, Schulz A, Skrabl-Baumgartner A, Starke S, Tarrant TK, Hershfield M, Grimbacher B, Hauck F.   +38 more
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Regulation of Microenvironments of Hydrogen-Bonded Organic Frameworks for Enhanced Enzyme Activity of Phosphotriesterase. [PDF]

Molecules
Wu F, Li P, Guo Y, Du C, Li P.
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Digestive Enzyme Activity and Temperature: Evolutionary Constraint or Physiological Flexibility? [PDF]

Animals (Basel)
Sagonas K, Paraskevopoulou F, Kotsakiozi P, Sozopoulos I, Pafilis P, Valakos ED.   +5 more
europepmc   +1 more source

ACTIVATION OF ENZYMES

Journal of Biological Chemistry, 1940
Marianna M. Richards, Leslie Hellerman
openaire   +1 more source